Analyst Soumit Roy of JonesTrading maintained a Buy rating on Curis, with a price target of $12.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Soumit Roy has given his Buy rating due to a combination of factors including anticipated significant data updates and strategic clinical developments. Curis is expected to present meaningful data from its PCNSL patient trials involving emavusertib and ibrutinib at the ASH 2025 conference. Additionally, the company is on track to enroll a substantial number of patients over the next year and a half, which could enhance its research outcomes.
Further supporting the Buy rating, Curis plans to update on the safety study of a triplet combination therapy for AML patients by the end of 2025, with further developments expected in 2026 for CLL patients. The company’s financial position, with a cash runway extending into the first quarter of 2026, provides a stable foundation for these endeavors. Despite potential risks such as clinical trial failures and competitive pressures, the projected peak sales and strategic milestones contribute to a positive outlook for Curis’s stock.
In another report released on August 5, H.C. Wainwright also reiterated a Buy rating on the stock with a $17.00 price target.